100 related articles for article (PubMed ID: 6574535)
21. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
Chou JC; Douyon R; Czobor P; Volavka J; Cooper TB
Psychiatry Res; 1998 Oct; 81(1):51-5. PubMed ID: 9829650
[TBL] [Abstract][Full Text] [Related]
22. Use of bromocriptine to prevent puerperal lactation during neuroleptic treatment of chronic schizophrenia.
Wolf R
Pharmacopsychiatry; 1992 Sep; 25(5):240-2. PubMed ID: 1357683
[TBL] [Abstract][Full Text] [Related]
23. Relation of plasma prolactin to clinical response in schizophrenic patients.
Gruen PG; Sachar EJ; Altman N; Langer G; Tabrizi MA; Halpern FS
Arch Gen Psychiatry; 1978 Oct; 35(10):1222-7. PubMed ID: 29592
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.
Lin CH; Kuo CC; Chou LS; Chen YH; Chen CC; Huang KH; Lane HY
J Clin Psychopharmacol; 2010 Oct; 30(5):518-25. PubMed ID: 20814315
[TBL] [Abstract][Full Text] [Related]
25. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Arvanitis LA; Miller BG
Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
[TBL] [Abstract][Full Text] [Related]
26. [Drug treatment of schizophrenic psychoses in puerperium].
Olbrich HM; Martin P
Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
[TBL] [Abstract][Full Text] [Related]
27. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
[TBL] [Abstract][Full Text] [Related]
28. Prolactin responses to domperidone in chronic schizophrenia.
Nerozzi D; Magnani A; Dastoli C; Ferri E; Capesciotti G; Antonozzi I; Frajese G; Meltzer HY
Psychiatry Res; 1992 May; 42(2):159-69. PubMed ID: 1631251
[TBL] [Abstract][Full Text] [Related]
29. Prolactin responses to neuroleptics in normal and schizophrenic subjects.
Gruen PH; Sachar EJ; Langer G; Altman N; Leifer M; Frantz A; Halpern FS
Arch Gen Psychiatry; 1978 Jan; 35(1):108-16. PubMed ID: 23087
[TBL] [Abstract][Full Text] [Related]
30. The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels.
Johnson GF; Hunt GE
Aust N Z J Psychiatry; 1980 Jun; 14(2):127-31. PubMed ID: 6932868
[TBL] [Abstract][Full Text] [Related]
31. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis.
Meltzer HY; Busch D
Psychiatry Res; 1983 Aug; 9(4):285-99. PubMed ID: 6580661
[TBL] [Abstract][Full Text] [Related]
32. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
33. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
34. Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings.
Hanssen T; Heyden T; Sundberg I; Alfredsson G; Nybäck H; Wetterberg L
Arch Gen Psychiatry; 1980 Jun; 37(6):685-90. PubMed ID: 7387339
[TBL] [Abstract][Full Text] [Related]
35. Prolactin bioassay in schizophrenia before and after neuroleptics.
Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
[TBL] [Abstract][Full Text] [Related]
36. Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.
Ravichandran GK; Lu RB; Shvartsburd A; Misra CH; Ho BT; Kahn M; Smith RC
Psychiatry Res; 1984 Jan; 11(1):61-9. PubMed ID: 6584932
[TBL] [Abstract][Full Text] [Related]
37. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.
Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T
Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871
[TBL] [Abstract][Full Text] [Related]
38. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
[No Abstract] [Full Text] [Related]
39. Plasma dopamine beta hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel).
Vardi J; Flechter S; Oberman Z; Segal R; Shogan G; Haker O
Encephale; 1981; 7(1):95-103. PubMed ID: 7227288
[TBL] [Abstract][Full Text] [Related]
40. [Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].
Wolf MA; Diener JM; Lajeunesse C; Shriqui C
J Psychiatry Neurosci; 1992 Jun; 17(2):68-71. PubMed ID: 1637801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
